Capecitabine in advanced hepatocellular carcinoma : A multicenter experience
Copyright © 2019. Published by Elsevier Ltd..
BACKGROUND: Recent data suggest a potential activity and a good tolerability of capecitabine in advanced hepatocellular carcinoma (HCC).
AIMS: To evaluate capecitabine activity and safety in a wide cohort of advanced HCC patients.
METHODS: Retrospective analysis of 143 capecitabine-treated patients (January 2010 to December 2017) in three centers of the Veneto Oncology Network.
RESULTS: Capecitabine was administered in second and third line, but also in first line instead of sorafenib in Child-Pugh B patients (70%), compromised clinical conditions (14%) or contraindications to antiangiogenetics (16%). Median overall survival (OS) and time to progression (TTP) were 6.9 and 2.8 months, respectively. There were no differences in OS and TTP between the 32 patients treated with non-metronomic scheme (2000 mg/day for 14 days) and the 111 patients treated with metronomic scheme (1000 mg/day) after correction for prognostic factors at baseline with a propensity score analysis. Capecitabine was more active in patients intolerant to sorafenib than in those progressing during treatment (p = 0.024). At least one adverse event (mainly hematological) was experienced by 73% of patients but discontinuation was necessary only in 11 (8%).
CONCLUSIONS: Capecitabine can be considered an active and safe option in advanced HCC, especially for patients unfit for other treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 51(2019), 12 vom: 04. Dez., Seite 1713-1719 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pelizzaro, Filippo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6804DJ8Z9U |
|---|
| Anmerkungen: |
Date Completed 21.05.2020 Date Revised 21.05.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.dld.2019.06.015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299327914 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299327914 | ||
| 003 | DE-627 | ||
| 005 | 20231225100107.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.dld.2019.06.015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0997.xml |
| 035 | |a (DE-627)NLM299327914 | ||
| 035 | |a (NLM)31320302 | ||
| 035 | |a (PII)S1590-8658(19)30672-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pelizzaro, Filippo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Capecitabine in advanced hepatocellular carcinoma |b A multicenter experience |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.05.2020 | ||
| 500 | |a Date Revised 21.05.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019. Published by Elsevier Ltd. | ||
| 520 | |a BACKGROUND: Recent data suggest a potential activity and a good tolerability of capecitabine in advanced hepatocellular carcinoma (HCC) | ||
| 520 | |a AIMS: To evaluate capecitabine activity and safety in a wide cohort of advanced HCC patients | ||
| 520 | |a METHODS: Retrospective analysis of 143 capecitabine-treated patients (January 2010 to December 2017) in three centers of the Veneto Oncology Network | ||
| 520 | |a RESULTS: Capecitabine was administered in second and third line, but also in first line instead of sorafenib in Child-Pugh B patients (70%), compromised clinical conditions (14%) or contraindications to antiangiogenetics (16%). Median overall survival (OS) and time to progression (TTP) were 6.9 and 2.8 months, respectively. There were no differences in OS and TTP between the 32 patients treated with non-metronomic scheme (2000 mg/day for 14 days) and the 111 patients treated with metronomic scheme (1000 mg/day) after correction for prognostic factors at baseline with a propensity score analysis. Capecitabine was more active in patients intolerant to sorafenib than in those progressing during treatment (p = 0.024). At least one adverse event (mainly hematological) was experienced by 73% of patients but discontinuation was necessary only in 11 (8%) | ||
| 520 | |a CONCLUSIONS: Capecitabine can be considered an active and safe option in advanced HCC, especially for patients unfit for other treatments | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Capecitabine | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a Systemic therapy | |
| 650 | 7 | |a Antimetabolites, Antineoplastic |2 NLM | |
| 650 | 7 | |a Capecitabine |2 NLM | |
| 650 | 7 | |a 6804DJ8Z9U |2 NLM | |
| 700 | 1 | |a Sammarco, Ambra |e verfasserin |4 aut | |
| 700 | 1 | |a Dadduzio, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Pastorelli, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Giovanis, Petros |e verfasserin |4 aut | |
| 700 | 1 | |a Soldà, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Rizzato, Mario Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Lombardi, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Lonardi, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Peserico, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Imondi, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Sartori, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Maddalo, Gemma |e verfasserin |4 aut | |
| 700 | 1 | |a Farinati, Fabio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver |d 2000 |g 51(2019), 12 vom: 04. Dez., Seite 1713-1719 |w (DE-627)NLM108968790 |x 1878-3562 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2019 |g number:12 |g day:04 |g month:12 |g pages:1713-1719 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.dld.2019.06.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2019 |e 12 |b 04 |c 12 |h 1713-1719 | ||